Point-of-care PSA testing: an evaluation of PSAwatch.

Area of Science:

• Urology
• Biochemistry
• Medical Diagnostics

Background:

• Prostate-specific antigen (PSA) is a key biomarker for prostate health.
• Accurate and accessible PSA testing is crucial for managing prostate disease.
• Current laboratory-based PSA assays require specialized equipment and multiple visits.

Purpose of the Study:

• To introduce and evaluate a novel quantitative, portable, point-of-care prostate-specific antigen (PSA) assay system.
• To assess the performance of the PSAwatch test and BioScan reader system against established laboratory methods.
• To determine the potential of this new system to improve patient convenience and reduce healthcare burdens.

Main Methods:

• A new quantitative prostate-specific antigen (PSA) assay, PSAwatch, was developed with a portable reader system, BioScan.
• Blood samples from 199 patients were analyzed using both the PSAwatch/BioScan system and standard laboratory PSA methods.
• The study focused on PSA concentrations within the range of 0.5 to 25 microg/l, analyzing 188 men within this range.

Main Results:

• The PSAwatch and BioScan system demonstrated good correlation with laboratory PSA measurements (R²=0.88).
• The system showed a standard error of 1.588 and a regression line bias of -0.02 at 4.00 microg/l.
• This represents the first report of a quantitative, portable, point-of-care PSA test and reader system.

Conclusions:

• The PSAwatch and BioScan system provides a reliable quantitative measurement of PSA at the point-of-care.
• This portable assay shows significant potential for improving the management of prostate disease.
• The system may reduce the need for hospital visits, enhancing patient convenience and potentially lowering healthcare costs.